Genetic variation in vitro and in vivo of an attenuated Lassa vaccine candidate

The attenuated Lassa vaccine candidate ML29 is a laboratory-produced reassortant between Lassa and Mopeia viruses, two Old World arenaviruses that differ by 40% in nucleic acid sequence. In our previous studies, ML29 elicited sterilizing immunity against Lassa virus challenge in guinea pigs and marm...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of virology Ročník 88; číslo 6; s. 3058
Hlavní autoři:	Zapata, Juan C, Goicochea, Marco, Nadai, Yuka, Eyzaguirre, Lindsay M, Carr, Jean K, Tallon, Luke J, Sadzewicz, Lisa, Myers, Garry, Fraser, Claire M, Su, Qi, Djavani, Mahmoud, Lukashevich, Igor S, Salvato, Maria S
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 01.03.2014
Témata:	Animals Callithrix Cercopithecus aethiops Genetic Variation Humans Immunity, Cellular Lassa Fever - immunology Lassa Fever - prevention & control Lassa Fever - virology Lassa virus - genetics Lassa virus - immunology Macaca mulatta Mice Mice, Inbred C57BL Mice, Inbred CBA Vaccines, Attenuated - genetics Vaccines, Attenuated - immunology Vero Cells Viral Vaccines - genetics Viral Vaccines - immunology
ISSN:	1098-5514, 1098-5514
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	The attenuated Lassa vaccine candidate ML29 is a laboratory-produced reassortant between Lassa and Mopeia viruses, two Old World arenaviruses that differ by 40% in nucleic acid sequence. In our previous studies, ML29 elicited sterilizing immunity against Lassa virus challenge in guinea pigs and marmosets and virus-specific cell-mediated immunity in both simian immunodeficiency virus (SIV)-infected and uninfected rhesus macaques. Here, we show that ML29 is stable after 12 passages in vitro without losing its plaque morphology or its attenuated phenotype in suckling mice. Additionally, we used deep sequencing to characterize the viral population comprising the original stock of ML29, the stock of ML29 after 12 passages in Vero cells, and the ML29 isolates obtained from vaccinated animals. Twenty-seven isolates bore approximately 77 mutations that exceeded 20% of the single-nucleotide polymorphism (SNP) changes at any single locus. Of these 77 mutations, 5 appeared to be host specific, for example, appearing in mice but not in primates. None of these mutations were reversions of ML29 to the sequences of the parental Lassa and Mopeia viruses. The host-specific mutations indicate viral adaptations to virus-host interactions, and such interactions make reasonable targets for antiviral approaches. Variants capable of chronic infection did not emerge from any of the primate infections, even in immune-deficient animals, indicating that the ML29 reassortant is reasonably stable in vivo. In conclusion, the preclinical studies of ML29 as a Lassa virus vaccine candidate have been advanced, showing high levels of protection in nonhuman primates and acceptable stability both in vitro and in vivo.
AbstractList	The attenuated Lassa vaccine candidate ML29 is a laboratory-produced reassortant between Lassa and Mopeia viruses, two Old World arenaviruses that differ by 40% in nucleic acid sequence. In our previous studies, ML29 elicited sterilizing immunity against Lassa virus challenge in guinea pigs and marmosets and virus-specific cell-mediated immunity in both simian immunodeficiency virus (SIV)-infected and uninfected rhesus macaques. Here, we show that ML29 is stable after 12 passages in vitro without losing its plaque morphology or its attenuated phenotype in suckling mice. Additionally, we used deep sequencing to characterize the viral population comprising the original stock of ML29, the stock of ML29 after 12 passages in Vero cells, and the ML29 isolates obtained from vaccinated animals. Twenty-seven isolates bore approximately 77 mutations that exceeded 20% of the single-nucleotide polymorphism (SNP) changes at any single locus. Of these 77 mutations, 5 appeared to be host specific, for example, appearing in mice but not in primates. None of these mutations were reversions of ML29 to the sequences of the parental Lassa and Mopeia viruses. The host-specific mutations indicate viral adaptations to virus-host interactions, and such interactions make reasonable targets for antiviral approaches. Variants capable of chronic infection did not emerge from any of the primate infections, even in immune-deficient animals, indicating that the ML29 reassortant is reasonably stable in vivo. In conclusion, the preclinical studies of ML29 as a Lassa virus vaccine candidate have been advanced, showing high levels of protection in nonhuman primates and acceptable stability both in vitro and in vivo.The attenuated Lassa vaccine candidate ML29 is a laboratory-produced reassortant between Lassa and Mopeia viruses, two Old World arenaviruses that differ by 40% in nucleic acid sequence. In our previous studies, ML29 elicited sterilizing immunity against Lassa virus challenge in guinea pigs and marmosets and virus-specific cell-mediated immunity in both simian immunodeficiency virus (SIV)-infected and uninfected rhesus macaques. Here, we show that ML29 is stable after 12 passages in vitro without losing its plaque morphology or its attenuated phenotype in suckling mice. Additionally, we used deep sequencing to characterize the viral population comprising the original stock of ML29, the stock of ML29 after 12 passages in Vero cells, and the ML29 isolates obtained from vaccinated animals. Twenty-seven isolates bore approximately 77 mutations that exceeded 20% of the single-nucleotide polymorphism (SNP) changes at any single locus. Of these 77 mutations, 5 appeared to be host specific, for example, appearing in mice but not in primates. None of these mutations were reversions of ML29 to the sequences of the parental Lassa and Mopeia viruses. The host-specific mutations indicate viral adaptations to virus-host interactions, and such interactions make reasonable targets for antiviral approaches. Variants capable of chronic infection did not emerge from any of the primate infections, even in immune-deficient animals, indicating that the ML29 reassortant is reasonably stable in vivo. In conclusion, the preclinical studies of ML29 as a Lassa virus vaccine candidate have been advanced, showing high levels of protection in nonhuman primates and acceptable stability both in vitro and in vivo. The attenuated Lassa vaccine candidate ML29 is a laboratory-produced reassortant between Lassa and Mopeia viruses, two Old World arenaviruses that differ by 40% in nucleic acid sequence. In our previous studies, ML29 elicited sterilizing immunity against Lassa virus challenge in guinea pigs and marmosets and virus-specific cell-mediated immunity in both simian immunodeficiency virus (SIV)-infected and uninfected rhesus macaques. Here, we show that ML29 is stable after 12 passages in vitro without losing its plaque morphology or its attenuated phenotype in suckling mice. Additionally, we used deep sequencing to characterize the viral population comprising the original stock of ML29, the stock of ML29 after 12 passages in Vero cells, and the ML29 isolates obtained from vaccinated animals. Twenty-seven isolates bore approximately 77 mutations that exceeded 20% of the single-nucleotide polymorphism (SNP) changes at any single locus. Of these 77 mutations, 5 appeared to be host specific, for example, appearing in mice but not in primates. None of these mutations were reversions of ML29 to the sequences of the parental Lassa and Mopeia viruses. The host-specific mutations indicate viral adaptations to virus-host interactions, and such interactions make reasonable targets for antiviral approaches. Variants capable of chronic infection did not emerge from any of the primate infections, even in immune-deficient animals, indicating that the ML29 reassortant is reasonably stable in vivo. In conclusion, the preclinical studies of ML29 as a Lassa virus vaccine candidate have been advanced, showing high levels of protection in nonhuman primates and acceptable stability both in vitro and in vivo.
Author	Salvato, Maria S Lukashevich, Igor S Djavani, Mahmoud Zapata, Juan C Su, Qi Tallon, Luke J Eyzaguirre, Lindsay M Myers, Garry Sadzewicz, Lisa Carr, Jean K Goicochea, Marco Fraser, Claire M Nadai, Yuka
Author_xml	– sequence: 1 givenname: Juan C surname: Zapata fullname: Zapata, Juan C organization: Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA – sequence: 2 givenname: Marco surname: Goicochea fullname: Goicochea, Marco – sequence: 3 givenname: Yuka surname: Nadai fullname: Nadai, Yuka – sequence: 4 givenname: Lindsay M surname: Eyzaguirre fullname: Eyzaguirre, Lindsay M – sequence: 5 givenname: Jean K surname: Carr fullname: Carr, Jean K – sequence: 6 givenname: Luke J surname: Tallon fullname: Tallon, Luke J – sequence: 7 givenname: Lisa surname: Sadzewicz fullname: Sadzewicz, Lisa – sequence: 8 givenname: Garry surname: Myers fullname: Myers, Garry – sequence: 9 givenname: Claire M surname: Fraser fullname: Fraser, Claire M – sequence: 10 givenname: Qi surname: Su fullname: Su, Qi – sequence: 11 givenname: Mahmoud surname: Djavani fullname: Djavani, Mahmoud – sequence: 12 givenname: Igor S surname: Lukashevich fullname: Lukashevich, Igor S – sequence: 13 givenname: Maria S surname: Salvato fullname: Salvato, Maria S
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/24335292$$D View this record in MEDLINE/PubMed
BookMark	eNpNkL1PwzAQxS1URD9gY0YeWVJ8_mjSEVVQiip1qViji3ORjFq7xE4k_nsiWiSmd-_d7254UzbywRNj9yDmALJ4ev_YzIUSymSgrtgExLLIjAE9-jeP2TTGTyFA64W-YWOplTJyKSdstyZPyVneY-swueC587x3qQ0cfX02feChGSzHlMh3mKjmW4wRhytrnSduB9bVw-KWXTd4iHR30Rnbv77sV2_ZdrferJ63mdVapYyggdxYmS90IxSCBoW1kWjBmoI0Kol1Y5GqSi_yWhXqN9GkICcpKjljj-e3pzZ8dRRTeXTR0uGAnkIXSzBCKmmW0gzowwXtqiPV5al1R2y_y78O5A9GDV7_
CitedBy_id	crossref_primary_10_1128_JVI_00307_15 crossref_primary_10_12688_f1000research_16989_1 crossref_primary_10_1016_j_jcv_2014_12_004 crossref_primary_10_1080_20477724_2017_1369643 crossref_primary_10_1136_bmjgh_2018_001116 crossref_primary_10_1038_s41392_024_01917_x crossref_primary_10_3389_fcimb_2024_1340017 crossref_primary_10_3390_v12040386
ContentType	Journal Article
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1128/JVI.03035-13
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Biology
EISSN	1098-5514
ExternalDocumentID	24335292
Genre	Journal Article Research Support, N.I.H., Extramural
GrantInformation_xml	– fundername: NIAID NIH HHS grantid: HHSN272200900009C – fundername: NIAID NIH HHS grantid: R01 AI093450 – fundername: NIAID NIH HHS grantid: R21 AI052367 – fundername: NCRR NIH HHS grantid: P51 RR000168 – fundername: NIAID NIH HHS grantid: AI052367 – fundername: NIAID NIH HHS grantid: U54 AI057168 – fundername: NIAID NIH HHS grantid: AI074790 – fundername: NIAID NIH HHS grantid: R21 AI074790 – fundername: NIAID NIH HHS grantid: R01 AI052367
GroupedDBID	--- -~X .55 .GJ 0R~ 18M 29L 2WC 39C 3O- 4.4 41~ 53G 5GY 5RE 5VS 6TJ 85S AAYJJ ABPPZ ACGFO ACNCT ADBBV AENEX AFFNX AGVNZ AI. ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW C1A CGR CS3 CUY CVF D0S DIK E3Z EBS ECM EIF EJD F5P FRP GX1 H13 HYE HZ~ IH2 KQ8 MVM N9A NPM O9- OHT OK1 P2P RHI RNS RPM RSF TR2 UPT VH1 W2D W8F WH7 WOQ X7M Y6R YQT ZGI ZXP ~02 ~KM 7X8 AAFWJ AAGFI AFPKN
ID	FETCH-LOGICAL-c443t-e1f175c2764f03a1413ad52ac1c58e4a32adfcaebb467d383a32ad4e317e20b2
IEDL.DBID	7X8
ISICitedReferencesCount	11
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000332126000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1098-5514
IngestDate	Sun Nov 09 13:04:27 EST 2025 Thu Apr 03 07:00:16 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	6
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c443t-e1f175c2764f03a1413ad52ac1c58e4a32adfcaebb467d383a32ad4e317e20b2
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
OpenAccessLink	https://jvi.asm.org/content/jvi/88/6/3058.full.pdf
PMID	24335292
PQID	1502325925
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_1502325925 pubmed_primary_24335292
PublicationCentury	2000
PublicationDate	2014-03-01
PublicationDateYYYYMMDD	2014-03-01
PublicationDate_xml	– month: 03 year: 2014 text: 2014-03-01 day: 01
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Journal of virology
PublicationTitleAlternate	J Virol
PublicationYear	2014
References	11371613 - Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6895-900 11987809 - Curr Top Microbiol Immunol. 2002;262:75-109 23402317 - Virol J. 2013;10:52 11289805 - Virology. 2001 Apr 10;282(2):230-6 23344562 - Viruses. 2013 Jan;5(1):241-78 21262835 - Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2396-401 17378212 - J Vector Borne Dis. 2007 Mar;44(1):1-11 16327776 - Nature. 2006 Jan 19;439(7074):344-8 20200234 - J Virol. 2010 May;84(10):5415-22 1585636 - Virology. 1992 Jun;188(2):600-5 3138361 - Kansenshogaku Zasshi. 1988 Mar;62 Suppl:353-66 15302945 - J Gen Virol. 2004 Sep;85(Pt 9):2515-23 10699137 - Pediatrics. 2000 Mar;105(3):E35 15266969 - Evolution. 2004 Jun;58(6):1185-94 7933157 - J Virol. 1994 Nov;68(11):7649-53 14512579 - J Virol. 2003 Oct;77(20):11296-8 19710144 - J Virol. 2009 Nov;83(21):11330-40 15019244 - Virus Res. 2004 Mar 15;100(2):249-55 19924222 - PLoS Negl Trop Dis. 2009;3(11):e548 11559805 - J Virol. 2001 Oct;75(20):9723-30 18692539 - Vaccine. 2008 Sep 26;26(41):5246-54 3367096 - J Exp Med. 1988 May 1;167(5):1719-24 17143722 - Virus Genes. 2007 Apr;34(2):169-76 15314228 - Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12588-91 19498020 - Blood. 2009 Aug 6;114(6):1196-204 21471230 - J Virol. 2011 Jun;85(12):6024-37 15220423 - J Virol. 2004 Jul;78(14):7498-507 12610166 - J Virol. 2003 Mar;77(6):3882-7 12215495 - Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12938-43 23420494 - J Vaccines Vaccin. 2012 Nov 20;3(7):null 17409137 - J Virol. 2007 Jun;81(12):6482-90 19727424 - Future Virol. 2008 Nov;3(6):553-566 19420075 - J Virol. 2009 Jul;83(14):7029-39 16940530 - J Virol. 2006 Sep;80(18):9192-9 7580496 - BMJ. 1995 Sep 30;311(7009):857-9 20943969 - J Virol. 2010 Dec;84(24):13059-62 20723216 - BMC Evol Biol. 2010;10:253 21085117 - Nature. 2010 Dec 9;468(7325):779-83 2813413 - Proc Natl Acad Sci U S A. 1989 Nov;86(21):8575-9 2705303 - Virology. 1989 Apr;169(2):377-84 16254329 - J Virol. 2005 Nov;79(22):13934-42 21159860 - J Virol. 2011 Mar;85(5):2266-75 16474141 - J Virol. 2006 Mar;80(5):2349-57 16220146 - PLoS Pathog. 2005 Oct;1(2):e11 22216135 - PLoS One. 2011;6(12):e28889 3581899 - Curr Top Microbiol Immunol. 1987;134:69-78 10623742 - J Virol. 2000 Jan;74(2):805-11
References_xml	– reference: 14512579 - J Virol. 2003 Oct;77(20):11296-8 – reference: 15266969 - Evolution. 2004 Jun;58(6):1185-94 – reference: 23402317 - Virol J. 2013;10:52 – reference: 23420494 - J Vaccines Vaccin. 2012 Nov 20;3(7):null – reference: 23344562 - Viruses. 2013 Jan;5(1):241-78 – reference: 15019244 - Virus Res. 2004 Mar 15;100(2):249-55 – reference: 16254329 - J Virol. 2005 Nov;79(22):13934-42 – reference: 20943969 - J Virol. 2010 Dec;84(24):13059-62 – reference: 16327776 - Nature. 2006 Jan 19;439(7074):344-8 – reference: 12215495 - Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12938-43 – reference: 3138361 - Kansenshogaku Zasshi. 1988 Mar;62 Suppl:353-66 – reference: 16940530 - J Virol. 2006 Sep;80(18):9192-9 – reference: 7580496 - BMJ. 1995 Sep 30;311(7009):857-9 – reference: 1585636 - Virology. 1992 Jun;188(2):600-5 – reference: 10699137 - Pediatrics. 2000 Mar;105(3):E35 – reference: 16220146 - PLoS Pathog. 2005 Oct;1(2):e11 – reference: 20200234 - J Virol. 2010 May;84(10):5415-22 – reference: 11289805 - Virology. 2001 Apr 10;282(2):230-6 – reference: 7933157 - J Virol. 1994 Nov;68(11):7649-53 – reference: 15302945 - J Gen Virol. 2004 Sep;85(Pt 9):2515-23 – reference: 19710144 - J Virol. 2009 Nov;83(21):11330-40 – reference: 16474141 - J Virol. 2006 Mar;80(5):2349-57 – reference: 3581899 - Curr Top Microbiol Immunol. 1987;134:69-78 – reference: 20723216 - BMC Evol Biol. 2010;10:253 – reference: 18692539 - Vaccine. 2008 Sep 26;26(41):5246-54 – reference: 3367096 - J Exp Med. 1988 May 1;167(5):1719-24 – reference: 19498020 - Blood. 2009 Aug 6;114(6):1196-204 – reference: 21262835 - Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2396-401 – reference: 22216135 - PLoS One. 2011;6(12):e28889 – reference: 11559805 - J Virol. 2001 Oct;75(20):9723-30 – reference: 11987809 - Curr Top Microbiol Immunol. 2002;262:75-109 – reference: 19420075 - J Virol. 2009 Jul;83(14):7029-39 – reference: 19924222 - PLoS Negl Trop Dis. 2009;3(11):e548 – reference: 2813413 - Proc Natl Acad Sci U S A. 1989 Nov;86(21):8575-9 – reference: 17143722 - Virus Genes. 2007 Apr;34(2):169-76 – reference: 11371613 - Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6895-900 – reference: 19727424 - Future Virol. 2008 Nov;3(6):553-566 – reference: 17409137 - J Virol. 2007 Jun;81(12):6482-90 – reference: 15220423 - J Virol. 2004 Jul;78(14):7498-507 – reference: 21159860 - J Virol. 2011 Mar;85(5):2266-75 – reference: 21085117 - Nature. 2010 Dec 9;468(7325):779-83 – reference: 15314228 - Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12588-91 – reference: 21471230 - J Virol. 2011 Jun;85(12):6024-37 – reference: 17378212 - J Vector Borne Dis. 2007 Mar;44(1):1-11 – reference: 12610166 - J Virol. 2003 Mar;77(6):3882-7 – reference: 10623742 - J Virol. 2000 Jan;74(2):805-11 – reference: 2705303 - Virology. 1989 Apr;169(2):377-84
SSID	ssj0014464
Score	2.191425
Snippet	The attenuated Lassa vaccine candidate ML29 is a laboratory-produced reassortant between Lassa and Mopeia viruses, two Old World arenaviruses that differ by...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	3058
SubjectTerms	Animals Callithrix Cercopithecus aethiops Genetic Variation Humans Immunity, Cellular Lassa Fever - immunology Lassa Fever - prevention & control Lassa Fever - virology Lassa virus - genetics Lassa virus - immunology Macaca mulatta Mice Mice, Inbred C57BL Mice, Inbred CBA Vaccines, Attenuated - genetics Vaccines, Attenuated - immunology Vero Cells Viral Vaccines - genetics Viral Vaccines - immunology
Title	Genetic variation in vitro and in vivo of an attenuated Lassa vaccine candidate
URI	https://www.ncbi.nlm.nih.gov/pubmed/24335292 https://www.proquest.com/docview/1502325925
Volume	88
WOSCitedRecordID	wos000332126000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpZ1LS8NAEIAHtQpefD_qixW8xjabTXdzEhGLSq09FOktbDa7kEtS-wj4751JUnoSBC-BTVgIm8nsNzsvgLsgMFHiiNy0tFRUW6EepGT3RBtnEACkXyUKD-RwqCaTaNQcuM2bsMqVTqwUdVoYOiPvILjg5h9GPHyYfnnUNYq8q00LjU1oBYgyJNVysvYioKlTeZWpZiaRwSrwnavO2-frPcp3EHrU2OA3uKw2mf7-f1_vAPYavGSPtTwcwobNj2Cnbjj5fQwfVGUaH7ESTeTqm7AsZ2W2mBVM52k9KAtWOBwyKr2ZLxFGUzZAxtY4y5AfnhnKhaGjghMY95_HTy9e01LBM0IEC8_6DnnBcNkTrhtoH7cwnYZcG9-EygodcJ06o22SoAJN0Xqt7giLlGF5N-GnsJUXuT0HFinn-5Zz2e0liFxCaRyhuZj0rJQqTNtwu1qoGCWW3BA6t8VyHq-Xqg1n9WrH07q0RswF5YBF_OIPsy9hF-lF1AFhV9By-L_aa9g25SKbz24qUcDrcPT-A9HBvNw
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Genetic+variation+in+vitro+and+in+vivo+of+an+attenuated+Lassa+vaccine+candidate&rft.jtitle=Journal+of+virology&rft.au=Zapata%2C+Juan+C&rft.au=Goicochea%2C+Marco&rft.au=Nadai%2C+Yuka&rft.au=Eyzaguirre%2C+Lindsay+M&rft.date=2014-03-01&rft.issn=1098-5514&rft.eissn=1098-5514&rft.volume=88&rft.issue=6&rft.spage=3058&rft_id=info:doi/10.1128%2FJVI.03035-13&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1098-5514&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1098-5514&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1098-5514&client=summon